
Today on Drug Discovery & Development
Complexity’s counterpoint: Understanding protocol optimization
In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints and procedures across all trial phases and therapeutic areas. This trend, driven by the increasing sophistication of trial designs, is evident across trial phases and major therapeutic areas. Resulting in more endpoints and procedures on…For sparse data classification, VersAI’s Extreme AutoML is more accurate and orders of magnitude faster than Google’s AutoML
A new AI technology known as VersAI, a proprietary AI technology from Verseon, is challenging the dominance of deep learning—especially in areas where data is scarce. In a recent preprint, Verseon researchers and a colleague at the Missouri University of Science and Technology show that VersAI can train predictive models considerably faster than Google AutoML, based…Drug Discovery and Development See More >

How a ‘rising tide’ of inclusivity is transforming clinical trials
Let’s say there’s a Black female patient with an aggressive form of breast cancer. She meets with her oncologist to discuss a promising targeted therapy that recently won FDA approval. The drug showed strong efficacy in clinical trials, with a 65% response rate. Yet when she asks about efficacy data specific to Black women, she…
Mary Marcus appointed CEO of NewAge Industries

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials

External comparator studies: What researchers need to know to minimize bias

Tiny breaths, big impacts: Bridging the gap between laboratory discoveries and clinical applications in breath research with mouse models
Sponsored Content See More >
Genomics/Proteomics See More >

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
In 2025, genetic validation is poised to emerge as a high-stakes litmus test in cardiovascular R&D, investors will continue to get better at funneling cash into proven science, and patients will continue their evolution to become more-active partners shaping their healthcare. To hear more about each of these trends, we considered feedback from three industry…

Genomics in 2025: How $500 whole genome sequencing could democratize genomic data

St. Jude pioneers gene editing and structural biology to advance pediatric research
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code

Athos Therapeutics chooses Vultr’s private cloud to power AI drug discovery engine
Infectious Disease See More >

Advances in next generation vaccine development for SARS-CoV-2
Typical COVID-19 vaccines present fragments of the SARS-CoV-2 spike protein to the body, enabling the immune system to recognize and develop a defense against the virus. However, emerging variants are increasingly evading this immune response due to mutations in their receptor-binding domain (RBD), threatening the effectiveness of existing vaccines. This challenge has prompted research into…

World AIDS Day Summit & Celebration slated for early December

Moderna and Pfizer win approval for KP.2 vaccine as KP.3 variants account for about half of current cases

Moderna’s single-dose mRNA RSV vaccine, mRESVIA, gains FDA approval for adults 60+

Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Oncology See More >

How 3T Biosciences’ platform targets immunologically cold solid tumors
Immunotherapy resistance in solid tumors remains one of oncology’s most significant therapeutic challenges, with multiple cancer types showing limited response to current approaches. Microsatellite stable colorectal cancer (MSS CRC) exemplifies this challenge, with over 90% of MSS CRC cases failing to respond to checkpoint inhibitor monotherapy, while resistance patterns also emerge in many other immunologically…